Elite Pharmaceuticals and SunGen Pharma File ANDA

Elite Pharmaceuticals (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration (FDA) for a generic version of an immediate release CNS stimulant.

As quoted in the press release:

“The filing of this ANDA represents the first of many products being developed under this Development and License Agreement with our partner, SunGen,” said Nasrat Hakim, President and CEO of Elite.  “In addition to our SequestOx™ NDA filing, Elite now has five ANDAs pending with the FDA.”

Click here to read the full press release.